Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750273 | 0.93 | HSPB1 (0.46) | HSPB1ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL16739110 | 0.91 | HSPB1 (0.46) | HSPB1ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL16739111 | 0.91 | HSPB1 (0.46) | HSPB1ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL16738885 | 0.85 | HSPB1 (0.52) | HSPB1ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL16739042 | 0.80 | HSPB1 (0.46) | HSPB1ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL16739041 | 0.76 | HSPB1 (0.54) | HSPB1ALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL3841711 | 0.74 | LMNA (0.55) | ALDH1A1KMT2ALMNAMEN1MAPT | |
| SCHEMBL30510897 | 0.74 | CYP19A1 (0.43) | ALDH1A1KMT2ALMNAMEN1MAPT | |
| SCHEMBL26039527 | 0.74 | CYP19A1 (0.43) | ALDH1A1KMT2ALMNAMEN1MAPT | |
| SCHEMBL9779937 | 0.72 | NPC1 (0.50) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9918990-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-9399640-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| WO-2015081203-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | HSPB1 960/4885ALDH1A1 4585/4885KMT2A 627/4885 |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | HSPB1 960/4885ALDH1A1 4585/4885KMT2A 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.